In recent years, China has taken considerably longer to approve new biotech crop “events” than have other countries. CropLife International (CLI) commissioned Agribusiness Consulting Group to conduct an analysis of the agricultural and broader economic impacts of these delays in Chinese approvals.
Agribusiness Intelligence's analysis was conducted in two phases. The first phase focuses on biotech events approved by China over the last six years, while the second phase addresses conditions over the next 3-5 years.1 This report addresses each phase separately.
Click below to download the full 100-page summary.